JP2023542701A - 薬学的製剤 - Google Patents

薬学的製剤 Download PDF

Info

Publication number
JP2023542701A
JP2023542701A JP2023519000A JP2023519000A JP2023542701A JP 2023542701 A JP2023542701 A JP 2023542701A JP 2023519000 A JP2023519000 A JP 2023519000A JP 2023519000 A JP2023519000 A JP 2023519000A JP 2023542701 A JP2023542701 A JP 2023542701A
Authority
JP
Japan
Prior art keywords
mitapibat
amount
pediatric subject
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023519000A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023542701A5 (https=
JPWO2022067039A5 (https=
Inventor
チュク－ユイ レオン，
エリック シモーネ，
オフィーリア チピン イン，
Original Assignee
アジオス ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アジオス ファーマシューティカルズ， インコーポレイテッド filed Critical アジオス ファーマシューティカルズ， インコーポレイテッド
Publication of JP2023542701A publication Critical patent/JP2023542701A/ja
Publication of JP2023542701A5 publication Critical patent/JP2023542701A5/ja
Publication of JPWO2022067039A5 publication Critical patent/JPWO2022067039A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2023519000A 2020-09-25 2021-09-24 薬学的製剤 Pending JP2023542701A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063083834P 2020-09-25 2020-09-25
US63/083,834 2020-09-25
US202063107196P 2020-10-29 2020-10-29
US63/107,196 2020-10-29
US202163238483P 2021-08-30 2021-08-30
US63/238,483 2021-08-30
PCT/US2021/051957 WO2022067039A1 (en) 2020-09-25 2021-09-24 Pharmaceutical formulation

Publications (3)

Publication Number Publication Date
JP2023542701A true JP2023542701A (ja) 2023-10-11
JP2023542701A5 JP2023542701A5 (https=) 2024-10-01
JPWO2022067039A5 JPWO2022067039A5 (https=) 2024-10-01

Family

ID=78179552

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023519000A Pending JP2023542701A (ja) 2020-09-25 2021-09-24 薬学的製剤

Country Status (10)

Country Link
US (1) US20230338283A1 (https=)
EP (1) EP4216956A1 (https=)
JP (1) JP2023542701A (https=)
KR (1) KR20230074536A (https=)
AU (1) AU2021347349A1 (https=)
CA (1) CA3196829A1 (https=)
IL (1) IL301596A (https=)
MX (1) MX2023003431A (https=)
TW (1) TW202228691A (https=)
WO (1) WO2022067039A1 (https=)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019104134A1 (en) * 2017-11-22 2019-05-31 Agios Pharmaceuticals, Inc. Crystalline forms of n-(4-(4-(cyclopropylmethyl) piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2561132C2 (ru) 2009-06-29 2015-08-20 Аджиос Фармасьютикалз, Инк. Производные хинолинсульфонамидов и их применение для модулирования пкм2 активности
FI3307271T3 (fi) 2015-06-11 2023-10-17 Agios Pharmaceuticals Inc Pyruvaattikinaasin aktivaattorien käyttämisen menetelmä

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019104134A1 (en) * 2017-11-22 2019-05-31 Agios Pharmaceuticals, Inc. Crystalline forms of n-(4-(4-(cyclopropylmethyl) piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BLOOD, vol. Vol.136(11), JPN6025049620, 10 September 2020 (2020-09-10), pages 1241 - 1249, ISSN: 0005743796 *
ファルマシア, vol. Vol.54(1), JPN6025049618, 2018, pages 75, ISSN: 0005743797 *

Also Published As

Publication number Publication date
US20230338283A1 (en) 2023-10-26
MX2023003431A (es) 2023-05-12
WO2022067039A1 (en) 2022-03-31
CA3196829A1 (en) 2022-03-31
KR20230074536A (ko) 2023-05-30
IL301596A (en) 2023-05-01
TW202228691A (zh) 2022-08-01
AU2021347349A1 (en) 2023-06-08
EP4216956A1 (en) 2023-08-02

Similar Documents

Publication Publication Date Title
DK2343070T3 (en) Pirfenidone therapy for patients with atypical liver function
AU2018335259B2 (en) High dosage valbenazine formulation and compositions, methods, and kits related thereto
KR20190142364A (ko) 펜플루라민을 사용하여 두즈 증후군을 치료하는 방법
Lechin et al. Neuropharmacologic treatment of bronchial asthma with the antidepressant tianeptine: A double‐blind, crossover placebo‐controlled study
US20240173333A1 (en) Treating Alagille Syndrome (ALGS)
JP2020535228A (ja) 患者集団中のけいれん発作の数および頻度の低減におけるフェンフルラミン製剤の使用法
JP2021527090A (ja) 老化関連神経変性の進行および／または発症を治療および／または予防するための方法および組成物
EP3316876A1 (en) Arginine silicate inositol for improving cognitive function
US20260076986A1 (en) A combination of scyllo-inositol and flavones
JP6991315B2 (ja) サルコペニアの予防剤及び治療剤
JP2023542701A (ja) 薬学的製剤
CN116568281A (zh) 药物制剂
TW202428284A (zh) 向患者提供依考匹泮（ｅｃｏｐｉｐａｍ）療法之方法
JP2024525424A (ja) 脳性麻痺によるジスキネジアの処置における使用のためのバルベナジン
Ross et al. P1498: initial data from the beacon trial: a phase 2, randomized, open-label trial of bitopertin in erythropoietic protoporphyria
IL303006A (en) Use of pyridofidine and analogues for the treatment of Rett syndrome
US20190247405A1 (en) Treatment of sma
Hughes et al. Pharmacokinetics and Pharmacodynamics of Levetiracetam in Neonatal Seizures: What We Still Need to Know
WO2026053257A1 (en) Method of treating muscular dystrophies
WO2025162430A1 (zh) 一种药物联用及其在预防或治疗神经退行性疾病中的用途
KR20240004683A (ko) 알펠리십 제형
KR20250165616A (ko) 고함량 단일 투여 단위 제형 및 이의 사용 방법
JP2024538054A (ja) 高シュウ酸尿症及び腎結石の治療のための１ｈ－１，２，３－トリアゾール－４－カルボン酸
Young et al. Diverse challenges in pediatric compounding: treating pulmonary hypertension, uncombable hair syndrome, and acanthamoeba keratitis
Balcioglu et al. Psychosurgery-indicated treatment-refractory obsessive-compulsive disorder: an overview through a case illustration

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240920

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240920

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260227